Meeting
2023 ASCO Genitourinary Cancers Symposium
Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Authors
Syed Arsalan Ahmed Naqvi
Mayo Clinic, Phoenix, AZ
Syed Arsalan Ahmed Naqvi , Irbaz Bin Riaz , Manal Imran , Muhammad Daim Bin Zafar , Kunwer Sufyan Faisal , Zaryab Bin Riaz , Parminder Singh , Alan Haruo Bryce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 195)
DOI
10.1200/JCO.2023.41.6_suppl.195
Abstract #
195
Poster Bd #
G8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
First Author: Syed Arsalan Ahmed Naqvi
Poster
2024 ASCO Genitourinary Cancers Symposium
Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.
First Author: Soumyajit Roy
Poster
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Tumor transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus who do not achieve an optimal PSA response to intensified androgen deprivation therapy (i-ADT).
First Author: Vinay Mathew Thomas